Pfizer Extends KnowledgeScan Software Agreement With BioWisdom | GenomeWeb
NEW YORK (GenomeWeb News) — BioWisdom will again use its KnowledgeScan software to help Pfizer in a drug-discovery project, BioWisdom said yesterday.
 
Pfizer plans to use the software to “assess the market opportunity, potential strategy, and clinical trial design” for an undisclosed class of compounds, BioWisdom said.
 
Financial terms of the agreement were not released.
 
A similar agreement was penned in June 2006. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.